Применение муколитических препаратов при бронхообструктивном синдроме

1. Овчаренко С. И. Бронхообструктивный синдром в практике врача-терапевта. Справочник поликлинического врача. 2011; 2: 38–41.
2. Braman SS. Chronic cough due to chronic bronchitis: ACCP evidence-based clinical practice guidelines. Chest 2006; 129 (Suppl. 1): 104S–115S.
3. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention (updated 2013). http://www.ginasthma.org
4. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. Available from: http://www.goldcopd.org/
5. Han MK, Agusti A, Calverley PM. Chronic Obstructive Pulmonary Disease Phenotypes. The Future of COPD. Am J Respir Crit Care Med; 2010; 182: 598–604.
6. Miravitlles M, Soler-Cataluña JJ, Calle M et al. Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Spanish Society of Pulmonology and Thoracic Surgery. Arch Bronconeumol 2012; 48 (7): 247–57.
7. Miravitlles M, Soler-Cataluña JJ, Calle M, Soriano JB. Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice. Eur Respir J 2013; 41 (6): 1252–6.
8. Malerba M, Ponticiello A, Radaeli A et al. Effect of twelve-months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double-blind, randomized, multicenter, placebo-controlled study (the AMETHIST Trial). Pulm Pharmacol Ther 2004; 17 (1): 27–34.
9. Jуnsson JS. Acute bronchitis and clinicaloutcome three years later: prospectivecohort study. BMJ 1998; 317: 1433.
10. Hallett JS. Recurrent acute bronchitis: the association with undiagnosed bronchial asthma. Ann Allergy 1985; 55: 568–70.
11. Melbye H, Kongerud J, Vorland L. Reversible airflow limitation in adults with respiratory infection. Eur Respir J 1994; 7: 1239–45.
12. Balsamo R, Lanata L, Egan CG. Mucoactive drugs. Eur Respir Rev 2010; 19 (116): 127–33.
13. Yamaya M, Nishimura H, Nadine LK et al. Ambroxol inhibits rhinovirus infection in primary cultures of human tracheal epithelial cells. Arch Pharm Res 2013.
14. Allegra R. Is there a place for oral mucolytics in the prevention of LRTI? ERS annual Congress 2009. http://www.ersnet.org
15. Schulz M, Hämmerlein A, Hinkel U et al. Safety and usage pattern of an over-the-counter ambroxol cough syrup: a community pharmacy-based cohort study. Int J Clin Pharmacol Ther 2006; 44 (9): 409–21.
16. Macfarlane J, Holmes W, Gard P et al. Prospective study of the incidence, aetiology and outcome of adult lower respiratory tract illness in the community. Thorax 2001; 56 (2): 109–14.
17. Poole P, Black PN, Cates CJ. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 8: CD001287.
18. Decramer M, Ruttenvan Molken M, Dekhuijzen PN et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomized placebo-controlled trial. Lancet 2005; 365 (9470): 1552–60.
19. Zheng JP, Kang J, Huang SG et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet 2008; 371 (9629): 2013–8.

К.А.Зыков1, Т.В.Тхоржевская1, Е.И.Соколов2

1. Лаборатория пульмонологии НИМСИ ГБОУ ВПО МГМСУ им. А.И.Евдокимова Минздрава России;
2. Кафедра факультетской терапии и профболезней ГБОУ ВПО МГМСУ им. А.И.Евдокимова Минздрава России